Publications by Guro Løvik Goll
49 publications found
Original articles
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Lancet Rheumatol, 6 (4), e226-e236
DOI 10.1016/S2665-9913(23)00341-7, PubMed 38402891
Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study
Front Immunol, 15, 1296273
DOI 10.3389/fimmu.2024.1296273, PubMed 38455062
Biosimilar tocilizumab-better access and lower cost?
Lancet Rheumatol, 6 (1), e6-e8
DOI 10.1016/S2665-9913(23)00268-0, PubMed 38258681
Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases
Arthritis Rheumatol (in press)
DOI 10.1002/art.42764, PubMed 37984460
Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients
EBioMedicine, 97, 104833
DOI 10.1016/j.ebiom.2023.104833, PubMed 37844534
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Rheumatology (Oxford) (in press)
DOI 10.1093/rheumatology/kead525, PubMed 37773994
HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases
J Intern Med, 293 (5), 648-655
DOI 10.1111/joim.13616, PubMed 36843323
Longitudinal changes of serum cytokines in patients with chronic low back pain and Modic changes
Osteoarthritis Cartilage, 31 (4), 543-547
DOI 10.1016/j.joca.2023.01.001, PubMed 36640896
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type
Scand J Gastroenterol, 58 (8), 874-882
DOI 10.1080/00365521.2023.2177884, PubMed 36788656
Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway
Expert Opin Biol Ther, 23 (12), 1203-1209
DOI 10.1080/14712598.2023.2273938, PubMed 37874218
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
Lancet Rheumatol, 5 (1), e36-e46
DOI 10.1016/S2665-9913(22)00330-7, PubMed 36415604
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
RMD Open, 8 (2)
DOI 10.1136/rmdopen-2022-002417, PubMed 36328399
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study
BMC Med, 20 (1), 378
DOI 10.1186/s12916-022-02587-8, PubMed 36199139
Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia
Scand J Gastroenterol, 58 (1), 25-33
DOI 10.1080/00365521.2022.2108684, PubMed 35996928
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy
Arthritis Rheumatol, 74 (8), 1321-1332
DOI 10.1002/art.42153, PubMed 35507355
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases
Ann Rheum Dis, 82 (1), 65-73
DOI 10.1136/annrheumdis-2022-222155, PubMed 35551063
Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
J Intern Med, 292 (3), 477-491
DOI 10.1111/joim.13495, PubMed 35411981
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
Lancet Rheumatol, 4 (3), e177-e187
DOI 10.1016/S2665-9913(21)00394-5, PubMed 34977602
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 326 (23), 2375-2384
DOI 10.1001/jama.2021.21316, PubMed 34932077
Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
RMD Open, 7 (3)
DOI 10.1136/rmdopen-2021-001985, PubMed 34911811
Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
Eur Heart J, 42 (39), 4064-4072
DOI 10.1093/eurheartj/ehab506, PubMed 34405870
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial
JAMA, 325 (17), 1744-1754
DOI 10.1001/jama.2021.4172, PubMed 33944876
Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
Rheumatol Int, 41 (9), 1657-1665
DOI 10.1007/s00296-021-04865-9, PubMed 33944985
Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study
Scand J Rheumatol, 50 (6), 445-454
DOI 10.1080/03009742.2021.1875040, PubMed 33650469
The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial
BMC Musculoskelet Disord, 21 (1), 698
DOI 10.1186/s12891-020-03720-5, PubMed 33087100
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
BioDrugs, 34 (5), 681-694
DOI 10.1007/s40259-020-00438-7, PubMed 32965617
Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
Trials, 21 (1), 13
DOI 10.1186/s13063-019-3734-4, PubMed 31907007
Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
Arthritis Res Ther, 21 (1), 256
DOI 10.1186/s13075-019-2009-5, PubMed 31783773
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
J Intern Med, 285 (6), 653-669
DOI 10.1111/joim.12880, PubMed 30762274
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Lancet, 389 (10086), 2304-2316
DOI 10.1016/S0140-6736(17)30068-5, PubMed 28502609
Interleukin-15 induces interleukin-17 production by synovial T cell lines from patients with rheumatoid arthritis
Scand J Immunol, 73 (3), 243-9
DOI 10.1111/j.1365-3083.2010.02498.x, PubMed 21204897
The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis
Ann Rheum Dis, 69 (6), 1110-6
DOI 10.1136/ard.2009.116384, PubMed 20439289
Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs
Ann Rheum Dis, 69 (5), 845-50
DOI 10.1136/ard.2009.122325, PubMed 20233753
Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study
Ann Rheum Dis, 69 (2), 345-51
DOI 10.1136/ard.2009.113092, PubMed 19648126
Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression
J Rheumatol, 36 (2), 266-72
DOI 10.3899/jrheum.080180, PubMed 19132792
A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients
Arthritis Res Ther, 10 (2), R28
DOI 10.1186/ar2381, PubMed 18312691
High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study
Ann Rheum Dis, 67 (2), 212-7
DOI 10.1136/ard.2006.068247, PubMed 17526555
Review articles
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
BioDrugs, 36 (6), 731-748
DOI 10.1007/s40259-022-00559-1, PubMed 36315391
Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
Rheumatology (Oxford), 56 (suppl_4), iv49-iv62
DOI 10.1093/rheumatology/kex276, PubMed 28903542
Other articles
Generic Tofacitinib-A More Affordable JAK Inhibitor
Mayo Clin Proc, 99 (1), 4-6
DOI 10.1016/j.mayocp.2023.11.014, PubMed 38176834
What Next after Biologic Therapy Fails in Rheumatoid Arthritis?
N Engl J Med, 383 (16), 1588-1589
DOI 10.1056/NEJMe2026142, PubMed 33053290
An Opportunity Missed: Biosimilars in the United States
Arthritis Rheumatol, 72 (7), 1046-1048
DOI 10.1002/art.41280, PubMed 32270925
Bio like drugs- just as good, much cheaper
Tidsskr. Nor. Laegeforen., 139 (6), 496
[Biosimilar drugs – just as good, and much cheaper]
Tidsskr Nor Laegeforen, 139 (6)
DOI 10.4045/tidsskr.19.0051, PubMed 30917643
New-generation JAK inhibitors: how selective can they be?
Lancet, 391 (10139), 2477-2478
DOI 10.1016/S0140-6736(18)31325-4, PubMed 29908671
The confidence of rheumatologists about switching to biosimilars for their patients
Joint Bone Spine, 85 (5), 507-509
DOI 10.1016/j.jbspin.2018.03.009, PubMed 29631065
Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care
Scand J Rheumatol, 47 (5), 418-421
DOI 10.1080/03009742.2017.1376110, PubMed 29310493
Metabolic profiling of synovial tissue shows altered glucose and choline metabolism in rheumatoid arthritis samples
Scand J Rheumatol, 46 (2), 160-161
DOI 10.3109/03009742.2016.1164242, PubMed 27098118
Theses
Recognition and effector functions of natural killer cells
Immunobiological Laboratory, Department of Anatomy, Institute of Basic Medical Sciences, University of Oslo, Oslo, 1 b. (flere pag.)
BIBSYS 010936564, ISBN 82-497-0019-8